ATX Amplia Therapeutics Limited
Healthcare · Biotechnology
· website
$0.14
52wk 0.10 – 0.28
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$69.30M
P/E (trailing)
—
P/E (forward)
-22.50
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
-0.40
EV / EBITDA
-4.68
Price / Book
1.75
ROE
-25.5%
Operating margin
-185.7%
Net margin
-160.9%
Total cash
$27.85M
Total debt
$341,111
Current ratio
19.78
Debt / Equity
0.01
Free cash flow
$-6.48M
Avg volume
1.03M
Latest annual results
(FY ending 31 Mar 2026)
- Revenue—
- Gross profit—
- Operating income-$13.18M
- Net income-$7.71M
- Diluted EPS-0.02
- Free cash flow-$8.77M
- Net debt-$27.51M